The Indian Pharmacopoeia Commission convened a two-day National Conference on "Quality and Safety of Biosimilars: Strengthening India's Biopharma SHAKTI Vision" on September 10–11, 2026, at C-CAMP, Bengaluru. According to Indian Pharma Post, the assembly drew 160 participants from regulatory, industry, and academic sectors. The proceedings produced a new authenticated reference substance and codified compliance expectations for manufacturers and surveillance authorities.
Regulatory scope
The agenda enumerated seven operational domains: pharmacopoeial standards, critical quality attributes, analytical characterization, comparability assessment, immunogenicity, pharmacovigilance, and evolving regulatory expectations. This configuration indicates a discernible shift toward integrated surveillance — manufacturers now confront simultaneous pressure to demonstrate physicochemical equivalence, biological function, and post-market safety within a unified compliance cycle. Dr. V. Kalaiselvan, Secretary-cum-Scientific Director of IPC, addressed the assembly on the necessity of reinforcing pharmacopoeial standards, reliable analytical evaluation, safety monitoring, and inter-agency cooperation. His remarks, as reported by Indian Pharma Post, also emphasized alignment with evolving regulatory expectations and support for biopharmaceutical innovation under the Viksit Bharat framework.
Enoxaparin Sodium IPRS release
The principal procedural output was the release of the Indian Pharmacopoeia Reference Substance (IPRS) for Enoxaparin Sodium, designated for bioassays. Enoxaparin is a low-molecular-weight heparin anticoagulant administered for prevention and treatment of thromboembolic disorders — a therapeutic category marked by high patient volumes and documented variance in generic bioactivity claims. The IPRS functions as an authenticated reference material, permitting consistent and comparable measurement of biological activity across manufacturing sites and reducing dependency on imported standards under the Atmanirbhar Bharat framework. Representation at the conference extended across regulatory authorities, industry, academia, and research institutions.
Surveillance implications
The convergence of pharmacopoeial standardization, indigenous reference substance availability, and pharmacovigilance in a single regulatory venue signals contraction of compliance thresholds for biosimilar manufacturers operating in or exporting to India. Healthcare providers should anticipate more stringent documentation requirements when adjudicating biosimilar substitution, particularly for low-molecular-weight heparins and analogous high-risk biologics. Variance in analytical methodology — a persistent and quantifiable concern across biosimilar evaluation — now has a calibrated reference baseline. The mitigation pathway is unambiguous: manufacturers and procurement authorities must synchronize quality protocols with the newly released IPRS specifications.